logo

Pluristem Therapeutics, Inc. (PSTI)



Trade PSTI now with
  Date
  Headline
1/9/2019 8:11:39 AM Pluristem Therapeutics Reports Successful Case Study In Treatment Of Buerger’s Disease Patient
1/3/2019 8:35:06 AM Pluristem Concludes Positive Meeting With FDA On Development Plan For Acute Radiation Syndrome
12/3/2018 7:28:24 AM Pluristem Presents Data From First Cohort Of Patients In Ongoing Phase I Clinical Trial Of PLX-R18
10/18/2018 6:33:51 AM Pluristem Therapeutics Selected To Present Data From Phase II IC Study At AHA Scientific Sessions
10/16/2018 7:02:59 AM Pluristem Therapeutics: FDA Approves Cost Recovery For PLX-PAD Under Expanded Access Program In Critical Limb Ischemia
10/10/2018 7:10:23 AM Pluristem Therapeutics Announces Publication In JCSM Of Two-Year Follow-Up Data From Phase I/II Study Of PLX-PAD
9/25/2018 5:33:48 AM Pluristem Therapeutics Says FDA Granted Orphan Drug Designation To PLX Cell Therapy
8/8/2018 7:04:27 AM Pluristem Begins Two Pivotal Phase III Studies In Israel
6/28/2018 7:06:08 AM BiondVax Appoints Mark Germain As Vice-Chairman Of Its Board
6/25/2018 7:07:37 AM Pluristem, Fukushima University Report Positive Data Of PLX-R18 Cells For Radiation Damage To GI Tract And Bone Marrow
6/12/2018 6:03:07 AM Pluristem Reports Positive Top-Line Results From Its Multinational Phase II Intermittent Claudication Study
6/4/2018 6:00:37 AM Pluristem To Announce Top-Line Results Of Its Multinational Phase II Intermittent Claudication Study On June 12, 2018
4/30/2018 7:13:31 AM U.S. FDA Clears Pluristem’s IND To Treat Victims Exposed To Acute Radiation
4/25/2018 7:14:46 AM FDA Clears Pluristem’s Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery
3/26/2018 7:06:46 AM Roger Jeffs, Former Co-CEO Of United Therapeutics, Joins Pluristem's Strategic Advisory Board
1/9/2018 7:09:18 AM FDA Clears Pluristem' EAP For Use Of PLX-PAD Cell Treatment In Patients With Critical Limb Ischemia